Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| U.S. GOLD CORP.USAU · Entity 6127 | Director | November 02, 2020 | November 04, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
U.S. GOLD CORP.
Report date November 02, 2020 · Filed November 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,015 |
Reported balance
After 2020-11-02 transaction · row 1
1 source rowRow 1 · 2020-11-02 · Grant · Acquired 600 · Balance 15,015 F1: Represents restricted shares of common stock awarded to the reporting person on November 2, 2020 pursuant to the U.S. Gold Corp. 2020 Stock Incentive Plan. Such shares vested immediately upon grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted shares of common stock awarded to the reporting person on November 2, 2020 pursuant to the U.S. Gold Corp. 2020 Stock Incentive Plan. Such shares vested immediately upon grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eloxx Pharmaceuticals, Inc.
Report date December 19, 2017 · Filed December 22, 2017
Section 16 reporting ended · disclosed 2017-12-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Company Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2027-12-19 | Direct | 18,190 |
Reported balance
After 2017-12-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-12-19 · Grant · Acquired 18,190 · Balance 18,190 F1: Such options were granted to Mr. Braca under Sevion Therapeutics Inc.'s ("Sevion's") 2008 Incentive Compensation Plan for services performed during Sevion's fiscal year ended June 30, 2017 and the portion of Sevion's fiscal year ended June 30, 2018 leading up to the closing of Sevion's transaction with Eloxx Pharmaceuticals, Ltd. (the "Transaction"), which occurred on December 19, 2017. In connection with the closing of the Transaction, Sevion effected a 1-for-20 reverse stock split and changed its corporate name to "Eloxx Pharmaceuticals, Inc." Such options were granted on a post-split basis and are immediately exercisable at an exercise price of $6.00 per share, which is equal to the closing selling price of Sevion's common stock on December 19, 2017, as reflected on a post-split basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Such options were granted to Mr. Braca under Sevion Therapeutics Inc.'s ("Sevion's") 2008 Incentive Compensation Plan for services performed during Sevion's fiscal year ended June 30, 2017 and the portion of Sevion's fiscal year ended June 30, 2018 leading up to the closing of Sevion's transaction with Eloxx Pharmaceuticals, Ltd. (the "Transaction"), which occurred on December 19, 2017. In connection with the closing of the Transaction, Sevion effected a 1-for-20 reverse stock split and changed its corporate name to "Eloxx Pharmaceuticals, Inc." Such options were granted on a post-split basis and are immediately exercisable at an exercise price of $6.00 per share, which is equal to the closing selling price of Sevion's common stock on December 19, 2017, as reflected on a post-split basis.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2020 Filed Nov 4, 2020 21:11 UTC | U.S. GOLD CORP. USAU · Entity 6127 | GrantCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-20-000027 · ownership.xml · nonDerivative · entry 1 BRACA JOHN N · CIK 0001267249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,015 F1 · shares: Represents restricted shares of common stock awarded to the reporting person on November 2, 2020 pursuant to the U.S. Gold Corp. 2020 Stock Incentive Plan. Such shares vested immediately upon grant. Read SEC document |
| September 17, 2020 Filed Sep 22, 2020 01:09 UTC | U.S. GOLD CORP. USAU · Entity 6127 | GrantStock Option (Right to Buy) · Derivative | 5,000 | Not disclosed Strike: $14.70 | Not disclosed |
DisclosureSEC source: 0001493152-20-018111 · ownership.xml · derivative · entry 3 BRACA JOHN N · CIK 0001267249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2022-12-22 F2 · kind: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 22, 2017 and vested 100% on December 22, 2018. The post-termination exercise period was extended to December 22, 2022. F2 · price: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 22, 2017 and vested 100% on December 22, 2018. The post-termination exercise period was extended to December 22, 2022. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 22, 2017 and vested 100% on December 22, 2018. The post-termination exercise period was extended to December 22, 2022. Read SEC document |
| September 17, 2020 Filed Sep 22, 2020 01:09 UTC | U.S. GOLD CORP. USAU · Entity 6127 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,000 | Not disclosed Strike: $14.70 | Not disclosed |
DisclosureSEC source: 0001493152-20-018111 · ownership.xml · derivative · entry 2 BRACA JOHN N · CIK 0001267249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-12-22 F3 · derivative.exercise_price: The securities and exercise prices shown have been adjusted from the time of grant to reflect the Issuer's 1-for-10 reverse stock split effected on March 19, 2020. F2 · kind: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 22, 2017 and vested 100% on December 22, 2018. The post-termination exercise period was extended to December 22, 2022. F3 · shares: The securities and exercise prices shown have been adjusted from the time of grant to reflect the Issuer's 1-for-10 reverse stock split effected on March 19, 2020. F2 · price: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 22, 2017 and vested 100% on December 22, 2018. The post-termination exercise period was extended to December 22, 2022. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 22, 2017 and vested 100% on December 22, 2018. The post-termination exercise period was extended to December 22, 2022. F3 · derivative.underlying_shares: The securities and exercise prices shown have been adjusted from the time of grant to reflect the Issuer's 1-for-10 reverse stock split effected on March 19, 2020. Read SEC document |
| September 17, 2020 Filed Sep 22, 2020 01:09 UTC | U.S. GOLD CORP. USAU · Entity 6127 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-018111 · ownership.xml · nonDerivative · entry 1 BRACA JOHN N · CIK 0001267249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,415 F1 · shares: Represents restricted shares of common stock awarded to the reporting person on September 17, 2020 pursuant to the U.S. Gold Corp. 2020 Stock Incentive Plan. Such shares vested immediately upon grant. Read SEC document |
| August 03, 2020 Filed Aug 3, 2020 23:42 UTC | U.S. GOLD CORP. USAU · Entity 6127 | GrantCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-014524 · ownership.xml · nonDerivative · entry 1 BRACA JOHN N · CIK 0001267249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,915 F1 · shares: Represents restricted shares of common stock awarded to the reporting person on August 3, 2020 pursuant to the U.S. Gold Corp. 2020 Stock Incentive Plan. Such shares vested immediately upon grant. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:36 UTC | U.S. GOLD CORP. USAU · Entity 6127 | GrantCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-007660 · ownership.xml · nonDerivative · entry 1 BRACA JOHN N · CIK 0001267249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,315 F1 · shares: Represents restricted shares of common stock awarded to the reporting person on May 1, 2020 pursuant to the U.S. Gold Corp. 2020 Stock Incentive Plan. Such shares vested immediately upon grant. F2 · balance_after: On March 19, 2020, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split on a post-split basis. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:30 UTC | U.S. GOLD CORP. USAU · Entity 6127 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-001644 · ownership.xml · nonDerivative · entry 1 BRACA JOHN N · CIK 0001267249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,154 F1 · shares: Represents restricted shares of common stock awarded to the reporting person on February 3, 2020 pursuant to the U.S. Gold Corp. 2020 Stock Incentive Plan. Such shares vested immediately upon grant. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 20:05 UTC | U.S. GOLD CORP. USAU · Entity 6127 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014361 · ownership.xml · nonDerivative · entry 1 BRACA JOHN N · CIK 0001267249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,154 F1 · shares: Represents restricted shares of common stock awarded to the reporting person on September 18, 2019 pursuant to the U.S. Gold Corp. 2020 Stock Incentive Plan. Such shares vested immediately upon grant. Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 13:00 UTC | U.S. GOLD CORP. USAU · Entity 6127 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-18-013327 · ownership.xml · nonDerivative · entry 1 BRACA JOHN N · CIK 0001267249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,154 F1 · security: Represents a restricted stock grant issued pursuant to the Issuer's 2017 Equity Incentive Plan which vests 50% on the date of issuance and 50% on the one-year anniversary of the date of issuance. Read SEC document |
| December 22, 2017 Filed Dec 27, 2017 23:39 UTC | U.S. GOLD CORP. USAU · Entity 6127 | GrantOption · Derivative | 50,000 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001493152-17-015136 · form4.xml · derivative · entry 1 BRACA JOHN N · CIK 0001267249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 50,000 shares Expires 2022-12-22 F2 · price: Option Award is compensation for the Reporting Person's service as a director of the Issuer. F1 · derivative.exercise_date: Represents an option award under the U.S. Gold Corp. Equity Incentive Plan (the "Option Award"), of which one-half shall vest immediately and one-half shall vest on the one year anniversary of the date of issuance. F3 · balance_after: Includes options vested or to be vested within 60 days pursuant to the Option Award. Read SEC document |
| December 19, 2017 Filed Dec 22, 2017 01:18 UTC | Eloxx Pharmaceuticals, Inc. SVOND · Entity 7180 | GrantCompany Stock Option · Derivative | 18,190 | Not disclosed Strike: $6.00 | Not disclosed |
DisclosureSEC source: 0001144204-17-064889 · tv481926_4.xml · derivative · entry 1 BRACA JOHN N · CIK 0001267249 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,190 Underlying: Common Stock · 18,190 shares Expires 2027-12-19 F1 · price: Such options were granted to Mr. Braca under Sevion Therapeutics Inc.'s ("Sevion's") 2008 Incentive Compensation Plan for services performed during Sevion's fiscal year ended June 30, 2017 and the portion of Sevion's fiscal year ended June 30, 2018 leading up to the closing of Sevion's transaction with Eloxx Pharmaceuticals, Ltd. (the "Transaction"), which occurred on December 19, 2017. In connection with the closing of the Transaction, Sevion effected a 1-for-20 reverse stock split and changed its corporate name to "Eloxx Pharmaceuticals, Inc." Such options were granted on a post-split basis and are immediately exercisable at an exercise price of $6.00 per share, which is equal to the closing selling price of Sevion's common stock on December 19, 2017, as reflected on a post-split basis. Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 15:30 UTC | U.S. GOLD CORP. USAU · Entity 6127 | GrantCommon Stock | 1,154 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-17-009838 · form4.xml · nonDerivative · entry 1 BRACA JOHN N · CIK 0001267249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,154 F1 · price: Issued pursuant to the Issuer's 2017 Equity Incentive Plan in consideration for the Reporting Person's role as a director of the Issuer for Board service for the period May 1, 2017 through July 31, 2017. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 23:30 UTC | Eloxx Pharmaceuticals, Inc. SVON · Entity 7180 | GrantCompany Stock Option · Derivative | 167,045 | $0.11 Strike: $0.22 | $18,374.95 |
DisclosureSEC source: 0001144204-17-009645 · v459866_form4.xml · derivative · entry 1 BRACA JOHN N · CIK 0001267249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,045 Underlying: Common Stock · 167,045 shares Expires 2027-02-14 F1 · shares: Such options were granted to Mr. Braca in lieu of cash compensation under the Company's independent director compensation plan and are immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.